Clinical Trials

Clinical Trial Detail

Return to search results.

Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD

Complete title: A Multi-center Phase II Study of Selective Depletion of CD45RA+ T cells from Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD

Research Study Number       2222.00
Principal Investigator       Marie Bleakley, MD
Phase       II

Look up trial at NIH

Research Study Description

The purpose of this study is to determine the effects, good or bad, of an experimental type of transplant in people with acute leukemia or advanced myelodysplastic syndromes. This study is being done to see whether or not this type of transplant protects study participants against graft-vs-host disease (GVHD). (GVHD is a complication that can happen after a transplant.)

The type of transplant used in this study is called a selective T-cell depleted transplant. Certain cells (CD45RA+ naive T-cells) will be removed from the donated stem cells in the laboratory after the cells are collected from the donor but before they are given to the study participant. The naïve T cells are thought to cause GVHD.

Participants will receive outpatient treatment at the Seattle Cancer Care Alliance (SCCA) and will be admitted to the University of Washington Medical Center (UWMC) or Seattle Children’s for those parts of their care requiring hospitalization.

All study procedures will be completed by about one year after transplant. After that point we will be monitoring study participants as part of the long-term follow-up program for post-transplant complications.

Eligibility Criteria (must meet the following to participate in this study)

• Diagnosed with acute lymphocytic leukemia (ALL) or acute myeloid leukemia (AML) or advanced myleodysplastic syndrome (MDS)

• Age 14-55

• Eligible for allogeneic hematopoietic stem cell transplantation (HSCT)

• Appropriately matched, sibling donor is available

Other eligibility criteria may apply.

Exclusions (conditions that would prevent participation in this study)

• Pregnant or breast-feeding

• Undergoing second hematopoietic stem cell transplantation (HSCT)

• Central nervous system (CNS) involvement that does not respond to intrathecal chemotherapy and/or standard cranial-spinal radiation

• HIV+

• Uncontrolled infections

• Organ dysfunction

• Known hypersensitivity to tacrolimus

Other exclusion criteria may apply.

Research Study Number       2222.00
Contact       Seattle Cancer Care Alliance Intake Office
Telephone       800-804-8824 / 206-288-1024

Acute Lymphoid Leukemia (ALL); Acute Myeloid Leukemia (AML); Bone Marrow and Hematopoietic Stem Cell Transplant (BMT and HSCT); Hematologic Malignancies; Leukemia; Childhood Cancers, Miscellaneous; Myelodysplastic and Myeloproliferative Syndromes (MDS and

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials

Fred Hutchinson Cancer Research Center is a world leader in research to prevent, detect and treat cancer and other life-threatening diseases.